Dynamically controlled asymmetric transmission of linearly polarized waves in VO_(2)-integrated Dirac semimetal metamaterials

We numerically demonstrated a novel chiral metamaterial to achieve broadband asymmetric transmission(AT)of linearly polarized electromagnetic waves in terahertz(THz)band.The proposed metamaterial unit cell exhibits no rotational symmetry with vanadium dioxide(VO_(2)) inclusion embedded between Dirac semimetals(DSMs)pattern.The resonant frequency of AT can be dynamically tunable by varying the Fermi energy(EF)of the DSMs.The insulator-to-metal phase transition of VO_(2) enables the amplitude of the AT to be dynamically tailored.The transmission coefficient|T_(yx)|can be adjusted from 0.756 to nearly 0 by modifying the conductivity of VO_(2).Meanwhile,the AT parameter intensity of linearly polarized incidence can be actively controlled from 0.55 to almost 0,leading to a switch for AT.When VO_(2)is in its insulator state,the proposed device achieves broadband AT parameter greater than 0.5 from 1.21 THz to 1.80 THz with a bandwidth of 0.59 THz.When the incident wave propagates along the backward(-z)direction,the cross-polarized transmission|T_(yx)|reaches a peak value 0.756 at 1.32 THz,whereas the value of|T_(xy)|well below 0.157 in the concerned frequency.On the other hand,the co-polarized transmission|T_(xx)|and|T_(yy)|remained equal in the whole frequency range.This work provides a novel approach in developing broadband,tunable,as well as switchable AT electromagnetic devices.

Alum colloid encapsulated insideβ-glucan particles enhance humoral and CTL immune responses of MUC1 vaccine

We have developed a MUC1 antigen-based antitumor vaccine loaded on alum colloid encapsulated insideβ-glucan particles(GP-Al).The constructed vaccine induced strong MUC1 antigen specific Ig G antibody titers and enhanced CD^(8+)T cells cytotoxic effect to kill tumor cells.These results indicated that GP-Al can be served as an efficient delivery system and adjuvant for the development of cancer vaccines especially small molecule antigens based cancer vaccines.

Enhancing the immune response and tumor suppression effect of antitumor vaccines adjuvanted with non-nucleotide small molecule STING agonist

Vaccine adjuvants have been widely used to enhance the immunogenicity of the antigens and elicit long-lasting immune response.However,only few vaccine adjuvants have been approved by the FDA for human use so far.Therefore,there is still an urgent need to develop novel adjuvants for the potential applications in clinical trials.Herein,non-nucleotide small molecule STING agonist di ABZI was employed to construct glycopeptide antigen based vaccines for the first time.Immunological evaluation indicated di ABZI not only enhanced the production of antibodies and T cell immune responses,but also inhibited tumor growth in tumor-bearing mice in glycopeptide-based subunit vaccines.These results indicated that di-ABZI demonstrates a high potential as adjuvant for the development of cancer vaccines.